Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 3
2004 2
2005 2
2006 4
2007 2
2008 2
2009 3
2010 1
2011 1
2012 3
2013 8
2014 11
2015 14
2016 13
2017 15
2018 11
2019 4
2020 9
2021 22
2022 24
2023 19
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Results by year

Filters applied: . Clear all
Page 1
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF; INDIGO Trial Investigators. Mellinghoff IK, et al. Among authors: arakawa y. N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272516 Clinical Trial.
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Kitagawa J, Aoi A, Nishikawa R. Narita Y, et al. Among authors: arakawa y. Neuro Oncol. 2021 Jan 30;23(1):122-133. doi: 10.1093/neuonc/noaa145. Neuro Oncol. 2021. PMID: 32583848 Free PMC article. Clinical Trial.
Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C.
Mishima K, Nishikawa R, Narita Y, Mizusawa J, Sumi M, Koga T, Sasaki N, Kinoshita M, Nagane M, Arakawa Y, Yoshimoto K, Shibahara I, Shinojima N, Asano K, Tsurubuchi T, Sasaki H, Asai A, Sasayama T, Momii Y, Sasaki A, Nakamura S, Kojima M, Tamaru JI, Tsuchiya K, Gomyo M, Abe K, Natsumeda M, Yamasaki F, Katayama H, Fukuda H. Mishima K, et al. Among authors: arakawa y. Neuro Oncol. 2023 Apr 6;25(4):687-698. doi: 10.1093/neuonc/noac246. Neuro Oncol. 2023. PMID: 36334050 Free PMC article. Clinical Trial.
Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.
Avila EK, Chamberlain M, Schiff D, Reijneveld JC, Armstrong TS, Ruda R, Wen PY, Weller M, Koekkoek JA, Mittal S, Arakawa Y, Choucair A, Gonzalez-Martinez J, MacDonald DR, Nishikawa R, Shah A, Vecht CJ, Warren P, van den Bent MJ, DeAngelis LM. Avila EK, et al. Among authors: arakawa y. Neuro Oncol. 2017 Jan;19(1):12-21. doi: 10.1093/neuonc/now190. Epub 2016 Sep 20. Neuro Oncol. 2017. PMID: 27651472 Free PMC article. Review.
Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study.
Nishikawa R, Yamasaki F, Arakawa Y, Muragaki Y, Narita Y, Tanaka S, Yamaguchi S, Mukasa A, Kanamori M. Nishikawa R, et al. Among authors: arakawa y. Jpn J Clin Oncol. 2023 Apr 29;53(5):371-377. doi: 10.1093/jjco/hyad001. Jpn J Clin Oncol. 2023. PMID: 36647599 Free PMC article.
RhoD Inhibits RhoC-ROCK-Dependent Cell Contraction via PAK6.
Durkin CH, Leite F, Cordeiro JV, Handa Y, Arakawa Y, Valderrama F, Way M. Durkin CH, et al. Among authors: arakawa y. Dev Cell. 2017 May 8;41(3):315-329.e7. doi: 10.1016/j.devcel.2017.04.010. Dev Cell. 2017. PMID: 28486133 Free PMC article.
163 results